Patent ID: 7531573

Claim:
A method for inhibiting unwanted non-malignant lymphoproliferation associated with an inflammatory disease, wherein the inflammatory disease is diarrhea; autoimmune disease; proliferative glomerulonephritis; lupus erythematosus; scleroderma; temporal arteritis; thromboangiitis obliterans; mucocutaneous lymph node syndrome; asthma; host versus graft; or inflammatory bowel disease; and wherein said method comprising the step of contacting a cell the proliferation of which contributes to inflammation in situ with an effective amount of a compound having the formula: or a pharmaceutically acceptable salt or hydrate thereof, wherein: n is 0, 1, 2, 3 or 4; X is absent, (C 1 -C 3 ) alkyl, (C 1 -C 3 ) alkenyl, or (C 1 -C 3 ) alkynyl; Y is C, N, P, Si or Ge; R 1 is absent, -halo, —R, —OR, —SR, —NR 2 , —ONR 2 , —NO 2 , —CN, —C(O)R, —C(S)R, —C(O)OR, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NR 2 , —C(S)NR 2 , —C(O)NR(OR), —C(S)NR(OR), —C(O)NR(SR), C(S)NR(SR), —CH(CN) 2 , —CH[C(O)R] 2 , —CH[C(S)R] 2 , —CH[C(O)OR] 2 , —CH[C(S)OR] 2 , —CH[C(O)SR] 2 , —CH[C(S)SR] 2 or aryl; Ar 1 is aryl, substituted aryl, heteroaryl other than imidazole, nitroimidazole and triazole, heteroarylium other than imidazolium, nitroimidazolium and triazolium, (C 5 -C 8 ) cycloalkyl or (C 5 -C 8 ) heterocycloalkyl; Ar 2 is aryl or substituted aryl; Ar 3 is aryl, substituted aryl, biaryl or heteroaryl other than imidazole, nitroimidazole and triazole; each R is independently selected from the group consisting of —H, (C 1 -C 6 ) alkyl, substituted (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, substituted (C 1 -C 6 ) alkenyl (C 1 -C 6 ) alkynyl, substituted (C 1 -C 6 ) alkynyl, and (C 1 -C 6 ) alkoxy; the aryl substituents are each independently selected from the group consisting of -halo, trihalomethyl, —R, —R′, —OR′, —SR′, NR′ 2 , —NO 2 , —CN, —C(O)R′, —C(S)R′, —C(O)OR′, —C(S)OR′, —C(O)SR′ and —C(S)SR′; the alkyl, alkenyl and alkynyl substituents are each independently selected from the group consisting of -halo, —R′, —OR′, —SR′, NR′ 2 , —NO 2 , —CN, —C(O)R′, —C(S)R′, —C(O)OR′, —C(S)OR′, —C(O)SR′, —C(S)SR′, aryl, γ-butyrolactonyl, pyrrolidinyl and succinic anhydridyl; and each R′ is independently selected from the group consisting of —H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl and (C 1 -C 6 ) alkynyl; wherein said administration is selected from the group consisting of oral, parenteral, intravenous, subcutaneous, transdermal and transmucosal for a living human.